These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25281463)

  • 1. Epidemiological differences in haematological malignancies between Europe and China.
    Chen XC; Chen XZ
    Lancet Oncol; 2014 Oct; 15(11):e471-2. PubMed ID: 25281463
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-drug interactions with tyrosine-kinase inhibitors.
    Croes S; de Vries F
    Lancet Oncol; 2014 Sep; 15(10):e416. PubMed ID: 25186045
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye.
    Yu G; Zheng QS; Wang DX; Zhou HH; Li GF
    Lancet Oncol; 2014 Oct; 15(11):e469-70. PubMed ID: 25281461
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Oct; 15(11):e470-1. PubMed ID: 25281462
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Jul; 15(8):e315-26. PubMed ID: 24988935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
    Keller KL; Franquiz MJ; Duffy AP; Trovato JA
    J Oncol Pharm Pract; 2018 Mar; 24(2):110-115. PubMed ID: 27941080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mecanisms of pharmacokinetic interactions involving oral anticancer agents].
    Levêque D; Duval C; Poulat C; Palas B; El Aatmani A; Dory A; Becker G; Gourieux B
    Bull Cancer; 2015 Jan; 102(1):65-72. PubMed ID: 25609481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis in rats.
    Pérez-Pitarch A; Guglieri-López B; Nacher A; Merino V; Merino-Sanjuan M
    Biopharm Drug Dispos; 2017 Jul; 38(5):315-325. PubMed ID: 28099756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption and elimination of imatinib through the rat intestine in vitro.
    Kralj E; Zakelj S; Trontelj J; Roškar R; Cernelč P; Kristl A
    Int J Pharm; 2014 Jan; 460(1-2):144-9. PubMed ID: 24219857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cobimetinib (Cotellic) for metastatic melanoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models.
    Sun H; Bi H; Huang M; Liu D; Qin Z
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):486-94. PubMed ID: 20936649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in bioavailability of small molecular tyrosine kinase inhibitors.
    Herbrink M; Nuijen B; Schellens JH; Beijnen JH
    Cancer Treat Rev; 2015 May; 41(5):412-22. PubMed ID: 25818541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of blood levels for oral anticancer drugs].
    van Erp NP; van der Graaf WT
    Ned Tijdschr Geneeskd; 2014; 158():A7884. PubMed ID: 25467023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism, and excretion of [
    Ye YE; Woodward CN; Narasimhan NI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does ponatinib cross the blood-brain barrier?
    Abid MB; De Mel S
    Br J Haematol; 2017 Nov; 179(3):497-498. PubMed ID: 27352067
    [No Abstract]   [Full Text] [Related]  

  • 17. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042
    [No Abstract]   [Full Text] [Related]  

  • 18. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O
    Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.